Funding Supports Further Clinical Development of Checkmate Pharmaceuticals TLR9 Agonist, CMP-001, in Melanoma and other Oncology Indications CAMBRIDGE, Mass., June 10, 2020-- Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million Series C financing. Checkmate plans to use the proceeds from the financing to support the continued clinical development of CMP-001 in anti-PD-1 refractory melanoma as well as to pursue studies in additional indications, such as front-line melanoma and head and neck squamous cell carcinoma.